{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:10:15Z","timestamp":1790028615119,"version":"4.0.1"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40259-022-00530-0","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T05:03:09Z","timestamp":1651035789000},"page":"341-358","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale"],"prefix":"10.1007","volume":"36","author":[{"given":"Fred","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiangkuo","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9467-5567","authenticated-orcid":false,"given":"Stephen D.","family":"Silberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"530_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/head.14024","volume":"61","author":"R Burch","year":"2021","unstructured":"Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021;61:60\u20138. https:\/\/doi.org\/10.1111\/head.14024.","journal-title":"Headache"},{"key":"530_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, et al. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21:137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0.","journal-title":"J Headache Pain"},{"key":"530_CR3","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/head.13407","volume":"58","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, et al. Migraine in America Symptoms and Treatment (MAST) study: baseline study methods, treatment patterns, and gender differences. Headache. 2018;58:1408\u201326. https:\/\/doi.org\/10.1111\/head.13407.","journal-title":"Headache"},{"key":"530_CR4","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.37765\/ajmc.2020.88547","volume":"26","author":"A Yucel","year":"2020","unstructured":"Yucel A, et al. Estimating the economic burden of migraine on US employers. Am J Manag Care. 2020;26:e403\u20138. https:\/\/doi.org\/10.37765\/ajmc.2020.88547.","journal-title":"Am J Manag Care."},{"key":"530_CR5","volume-title":"Headache: and other head pain","author":"H Wolff","year":"1963","unstructured":"Wolff H. Headache: and other head pain. Oxford: Oxford University Press; 1963."},{"key":"530_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/ana.410160202","volume":"16","author":"MA Moskowitz","year":"1984","unstructured":"Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol. 1984;16:157\u201368. https:\/\/doi.org\/10.1002\/ana.410160202.","journal-title":"Ann Neurol"},{"key":"530_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0304-3940(85)90296-4","volume":"62","author":"R Uddman","year":"1985","unstructured":"Uddman R, et al. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett. 1985;62:131\u20136. https:\/\/doi.org\/10.1016\/0304-3940(85)90296-4.","journal-title":"Neurosci Lett"},{"key":"530_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1146\/annurev-pharmtox-010814-124701","volume":"55","author":"AF Russo","year":"2015","unstructured":"Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533\u201352. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010814-124701.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"530_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/cne.903090408","volume":"309","author":"JT Keller","year":"1991","unstructured":"Keller JT, Marfurt CF. Peptidergic and serotoninergic innervation of the rat dura mater. J Comp Neurol. 1991;309:515\u201334. https:\/\/doi.org\/10.1002\/cne.903090408.","journal-title":"J Comp Neurol"},{"key":"530_CR10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/0166-2236(85)90050-5","volume":"8","author":"L Edvinsson","year":"1985","unstructured":"Edvinsson L. Functional role of perivascular peptides in the control of cerebral circulation. Trends Neurosci. 1985;8:126\u201331. https:\/\/doi.org\/10.1016\/0166-2236(85)90050-5.","journal-title":"Trends Neurosci"},{"key":"530_CR11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, et al. CGRP as the target of new migraine therapies\u2014successful translation from bench to clinic. Nat Rev Neurol. 2018;14:338\u201350. https:\/\/doi.org\/10.1038\/s41582-018-0003-1.","journal-title":"Nat Rev Neurol"},{"key":"530_CR12","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40259-017-0250-5","volume":"31","author":"H Yuan","year":"2017","unstructured":"Yuan H, et al. CGRP monoclonal antibodies for migraine: rationale and progress. BioDrugs. 2017;31:487\u2013501. https:\/\/doi.org\/10.1007\/s40259-017-0250-5.","journal-title":"BioDrugs"},{"key":"530_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1124\/jpet.115.227793","volume":"356","author":"L Shi","year":"2016","unstructured":"Shi L, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther. 2016;356:223\u201331. https:\/\/doi.org\/10.1124\/jpet.115.227793.","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 3","key":"530_CR14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/head.13379","volume":"58","author":"SJ Tepper","year":"2018","unstructured":"Tepper SJ. History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment. Headache. 2018;58(Suppl 3):238\u201375. https:\/\/doi.org\/10.1111\/head.13379.","journal-title":"Headache"},{"key":"530_CR15","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1177\/0333102419840780","volume":"39","author":"W Kielbasa","year":"2019","unstructured":"Kielbasa W, Helton DL. A new era for migraine: pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia. 2019;39:1284\u201397. https:\/\/doi.org\/10.1177\/0333102419840780.","journal-title":"Cephalalgia"},{"key":"530_CR16","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","volume":"15","author":"H Sun","year":"2016","unstructured":"Sun H, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:382\u201390. https:\/\/doi.org\/10.1016\/S1474-4422(16)00019-3.","journal-title":"Lancet Neurol"},{"key":"530_CR17","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, et al. Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 2021;28:1716\u201325. https:\/\/doi.org\/10.1111\/ene.14715.","journal-title":"Eur J Neurol"},{"key":"530_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425\u201334. https:\/\/doi.org\/10.1016\/S1474-4422(17)30083-2.","journal-title":"Lancet Neurol"},{"key":"530_CR19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/0333102420912726","volume":"40","author":"SJ Tepper","year":"2020","unstructured":"Tepper SJ, et al. Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia. 2020;40:543\u201353. https:\/\/doi.org\/10.1177\/0333102420912726.","journal-title":"Cephalalgia"},{"key":"530_CR20","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1705848.","journal-title":"N Engl J Med"},{"key":"530_CR21","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1212\/WNL.0000000000010019","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, et al. One-year sustained efficacy of erenumab in episodic migraine: results of the STRIVE study. Neurology. 2020;95:e469\u201379. https:\/\/doi.org\/10.1212\/WNL.0000000000010019.","journal-title":"Neurology"},{"key":"530_CR22","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026\u201337. https:\/\/doi.org\/10.1177\/0333102418759786.","journal-title":"Cephalalgia"},{"key":"530_CR23","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/s0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392:2280\u20137. https:\/\/doi.org\/10.1016\/s0140-6736(18)32534-0.","journal-title":"Lancet"},{"key":"530_CR24","doi-asserted-by":"publisher","first-page":"e2724","DOI":"10.1212\/WNL.0000000000012029","volume":"96","author":"PJ Goadsby","year":"2021","unstructured":"Goadsby PJ, et al. Long-term efficacy and safety of Erenumab: results from 64 weeks of the LIBERTY study. Neurology. 2021;96:e2724\u201335. https:\/\/doi.org\/10.1212\/WNL.0000000000012029.","journal-title":"Neurology"},{"key":"530_CR25","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1111\/head.13652","volume":"59","author":"F Sakai","year":"2019","unstructured":"Sakai F, et al. A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache. 2019;59:1731\u201342. https:\/\/doi.org\/10.1111\/head.13652.","journal-title":"Headache"},{"key":"530_CR26","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/head.14138","volume":"61","author":"T Takeshima","year":"2021","unstructured":"Takeshima T, et al. Erenumab treatment for migraine prevention in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. Headache. 2021;61:927\u201335. https:\/\/doi.org\/10.1111\/head.14138.","journal-title":"Headache"},{"key":"530_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211053571","author":"U Reuter","year":"2021","unstructured":"Reuter U, et al. Erenumab versus topiramate for the prevention of migraine\u2014a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. 2021. https:\/\/doi.org\/10.1177\/03331024211053571.","journal-title":"Cephalalgia"},{"key":"530_CR28","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1177\/03331024211024160","volume":"41","author":"SJ Wang","year":"2021","unstructured":"Wang SJ, et al. Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study. Cephalalgia. 2021;41:1285\u201397. https:\/\/doi.org\/10.1177\/03331024211024160.","journal-title":"Cephalalgia"},{"key":"530_CR29","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/head.14096","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, et al. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine. Headache. 2021;61:653\u201361. https:\/\/doi.org\/10.1111\/head.14096.","journal-title":"Headache"},{"key":"530_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s10194-021-01313-8","volume":"22","author":"K Hirata","year":"2021","unstructured":"Hirata K, et al. Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial. J Headache Pain. 2021;22:110. https:\/\/doi.org\/10.1186\/s10194-021-01313-8.","journal-title":"J Headache Pain"},{"key":"530_CR31","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","volume":"92","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ, et al. Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology. 2019;92:e2309\u201320. https:\/\/doi.org\/10.1212\/WNL.0000000000007497.","journal-title":"Neurology"},{"key":"530_CR32","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1136\/jnnp-2020-324396","volume":"92","author":"M Lanteri-Minet","year":"2021","unstructured":"Lanteri-Minet M, et al. Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2\u20134 preventives were not useful: results from the LIBERTY study. J Neurol Neurosurg Psychiatry. 2021;92:466\u201372. https:\/\/doi.org\/10.1136\/jnnp-2020-324396.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"530_CR33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40265-019-01069-1","volume":"79","author":"S Lattanzi","year":"2019","unstructured":"Lattanzi S, et al. Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety. Drugs. 2019;79:417\u201331. https:\/\/doi.org\/10.1007\/s40265-019-01069-1.","journal-title":"Drugs"},{"key":"530_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4678","author":"M Ashina","year":"2021","unstructured":"Ashina M, et al. Assessment of erenumab safety and efficacy in patients with migraine with and without aura: a secondary analysis of randomized clinical trials. JAMA Neurol. 2021. https:\/\/doi.org\/10.1001\/jamaneurol.2021.4678.","journal-title":"JAMA Neurol"},{"key":"530_CR35","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1212\/WNL.0000000000008743","volume":"94","author":"D Kudrow","year":"2020","unstructured":"Kudrow D, et al. Vascular safety of erenumab for migraine prevention. Neurology. 2020;94:e497\u2013510. https:\/\/doi.org\/10.1212\/WNL.0000000000008743.","journal-title":"Neurology"},{"key":"530_CR36","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1177\/0333102419854082","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, et al. Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia. 2019;39:1455\u201364. https:\/\/doi.org\/10.1177\/0333102419854082.","journal-title":"Cephalalgia"},{"key":"530_CR37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/978-3-030-69032-8_9","volume-title":"Monoclonal antibodies in headache","author":"TP Do","year":"2021","unstructured":"Do TP, Younis S, Ashina M. Erenumab. In: van den Brink AM, Martelletti P, editors. Monoclonal antibodies in headache. Cham: Springer; 2021. p. 121\u20139."},{"key":"530_CR38","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/head.14032","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, et al. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache. 2021;61:363\u201372. https:\/\/doi.org\/10.1111\/head.14032.","journal-title":"Headache"},{"key":"530_CR39","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.14194","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, et al. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: results of the EARLY 2 study. Headache. 2021;61:1351\u201363. https:\/\/doi.org\/10.1111\/head.14194.","journal-title":"Headache"},{"key":"530_CR40","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40120-021-00245-4","volume":"10","author":"E Faust","year":"2021","unstructured":"Faust E, et al. Real-world treatment profiles, clinical outcomes, and healthcare resource utilization of patients with migraine prescribed erenumab: a multicenter chart-review study of US headache centers. Neurol Ther. 2021;10:293\u2013306. https:\/\/doi.org\/10.1007\/s40120-021-00245-4.","journal-title":"Neurol Ther."},{"key":"530_CR41","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/head.13951","volume":"60","author":"J Robblee","year":"2020","unstructured":"Robblee J, et al. Real-world patient experience with erenumab for the preventive treatment of migraine. Headache. 2020;60:2014\u201325. https:\/\/doi.org\/10.1111\/head.13951.","journal-title":"Headache"},{"key":"530_CR42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, et al. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020;21:61. https:\/\/doi.org\/10.1186\/s10194-020-01127-0.","journal-title":"J Headache Pain"},{"key":"530_CR43","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1177\/0333102420946725","volume":"40","author":"S Kanaan","year":"2020","unstructured":"Kanaan S, et al. Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia. 2020;40:1511\u201322. https:\/\/doi.org\/10.1177\/0333102420946725.","journal-title":"Cephalalgia"},{"key":"530_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21:32. https:\/\/doi.org\/10.1186\/s10194-020-01102-9.","journal-title":"J Headache Pain"},{"key":"530_CR45","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/head.13832","volume":"60","author":"M Silvestro","year":"2020","unstructured":"Silvestro M, et al. Erenumab efficacy on comorbid cluster headache in patients with migraine: a real-world case series. Headache. 2020;60:1187\u201395. https:\/\/doi.org\/10.1111\/head.13832.","journal-title":"Headache"},{"key":"530_CR46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-3-030-69032-8_7","volume-title":"Monoclonal antibodies in headache: from bench to patient","author":"U Reuter","year":"2021","unstructured":"Reuter U, Raffaelli B. Galcanezumab. In: van den Brink AM, Martelletti P, editors. Monoclonal antibodies in headache: from bench to patient. Cham: Springer; 2021. p. 99\u2013108."},{"key":"530_CR47","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S1474-4422(14)70128-0","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW, et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014;13:885\u201392. https:\/\/doi.org\/10.1016\/S1474-4422(14)70128-0.","journal-title":"Lancet Neurol"},{"key":"530_CR48","doi-asserted-by":"publisher","first-page":"251581632093257","DOI":"10.1177\/2515816320932573","volume":"3","author":"F Sakai","year":"2020","unstructured":"Sakai F, Ozeki A, Skljarevski V. Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: a phase 2 randomized controlled clinical trial. Cephalalgia Rep. 2020;3:2515816320932573. https:\/\/doi.org\/10.1177\/2515816320932573.","journal-title":"Cephalalgia Rep."},{"key":"530_CR49","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75:1080\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1212.","journal-title":"JAMA Neurol"},{"key":"530_CR50","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38:1442\u201354. https:\/\/doi.org\/10.1177\/0333102418779543.","journal-title":"Cephalalgia"},{"key":"530_CR51","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, et al. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91:e2211\u201321. https:\/\/doi.org\/10.1212\/WNL.0000000000006640.","journal-title":"Neurology"},{"key":"530_CR52","doi-asserted-by":"crossref","first-page":"P2.10","DOI":"10.1212\/WNL.92.15_supplement.P2.10-010","volume":"92","author":"H Detke","year":"2019","unstructured":"Detke H, et al. One-year treatment with Galcanezumab in patients with chronic migraine: results from the open-label phase of the REGAIN study (P2.10\u2013010). Neurology. 2019;92:P2.10-010.","journal-title":"Neurology"},{"key":"530_CR53","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa1813440","volume":"381","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, et al. Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med. 2019;381:132\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1813440.","journal-title":"N Engl J Med"},{"key":"530_CR54","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1177\/0333102420905321","volume":"40","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, et al. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment. Cephalalgia. 2020;40:935\u201348. https:\/\/doi.org\/10.1177\/0333102420905321.","journal-title":"Cephalalgia"},{"key":"530_CR55","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19:814\u201325. https:\/\/doi.org\/10.1016\/S1474-4422(20)30279-9.","journal-title":"Lancet Neurol"},{"key":"530_CR56","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1007\/s12325-021-01911-7","volume":"38","author":"U Reuter","year":"2021","unstructured":"Reuter U, et al. Galcanezumab in patients with multiple previous migraine preventive medication category failures: results from the open-label period of the CONQUER trial. Adv Ther. 2021;38:5465\u201383. https:\/\/doi.org\/10.1007\/s12325-021-01911-7.","journal-title":"Adv Ther"},{"key":"530_CR57","doi-asserted-by":"publisher","first-page":"175628642091808","DOI":"10.1177\/1756286420918088","volume":"13","author":"P Gklinos","year":"2020","unstructured":"Gklinos P, Mitsikostas DD. Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Neurol Disord. 2020;13:1756286420918088. https:\/\/doi.org\/10.1177\/1756286420918088.","journal-title":"Ther Adv Neurol Disord"},{"key":"530_CR58","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/0333102420966658","volume":"41","author":"DW Dodick","year":"2021","unstructured":"Dodick DW, et al. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia. 2021;41:340\u201352. https:\/\/doi.org\/10.1177\/0333102420966658.","journal-title":"Cephalalgia"},{"key":"530_CR59","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12883-018-1193-2","volume":"18","author":"A Camporeale","year":"2018","unstructured":"Camporeale A, et al. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurol. 2018;18:188. https:\/\/doi.org\/10.1186\/s12883-018-1193-2.","journal-title":"BMC Neurol"},{"key":"530_CR60","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, et al. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain. 2021;22:35. https:\/\/doi.org\/10.1186\/s10194-021-01247-1.","journal-title":"J Headache Pain"},{"key":"530_CR61","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/14740338.2021.1866536","volume":"20","author":"K Hirata","year":"2021","unstructured":"Hirata K, et al. A long-term open-label safety study of galcanezumab in Japanese patients with migraine. Expert Opin Drug Saf. 2021;20:721\u201333. https:\/\/doi.org\/10.1080\/14740338.2021.1866536.","journal-title":"Expert Opin Drug Saf"},{"key":"530_CR62","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/978-3-030-69032-8_10","volume-title":"Monoclonal antibodies in headache","author":"L Lionetto","year":"2021","unstructured":"Lionetto L, et al. Fremanezumab. In: van den Brink AM, Martelletti P, editors., et al., Monoclonal antibodies in headache. Cham: Springer; 2021. p. 131\u20136."},{"key":"530_CR63","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1474-4422(15)00249-5","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14:1081\u201390. https:\/\/doi.org\/10.1016\/S1474-4422(15)00249-5.","journal-title":"Lancet Neurol"},{"key":"530_CR64","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(15)00245-8","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14:1091\u2013100. https:\/\/doi.org\/10.1016\/S1474-4422(15)00245-8.","journal-title":"Lancet Neurol"},{"key":"530_CR65","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1709038.","journal-title":"N Engl J Med"},{"key":"530_CR66","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319:1999\u20132008. https:\/\/doi.org\/10.1001\/jama.2018.4853.","journal-title":"JAMA"},{"key":"530_CR67","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology. 2020;95:e2487\u201399. https:\/\/doi.org\/10.1212\/WNL.0000000000010600.","journal-title":"Neurology"},{"key":"530_CR68","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394:1030\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(19)31946-4.","journal-title":"Lancet"},{"key":"530_CR69","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/head.14169","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, et al. Efficacy and safety of fremanezumab for chronic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache. 2021;61:1092\u2013101. https:\/\/doi.org\/10.1111\/head.14169.","journal-title":"Headache"},{"key":"530_CR70","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s10194-020-01173-8","volume":"21","author":"SD Silberstein","year":"2020","unstructured":"Silberstein SD, et al. The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain. 2020;21:114. https:\/\/doi.org\/10.1186\/s10194-020-01173-8.","journal-title":"J Headache Pain"},{"key":"530_CR71","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/head.14097","volume":"61","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, et al. Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study. Headache. 2021;61:662\u201372. https:\/\/doi.org\/10.1111\/head.14097.","journal-title":"Headache"},{"key":"530_CR72","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s10194-021-01336-1","volume":"22","author":"A MaassenVanDenBrink","year":"2021","unstructured":"MaassenVanDenBrink A, et al. Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study. J Headache Pain. 2021;22:152. https:\/\/doi.org\/10.1186\/s10194-021-01336-1.","journal-title":"J Headache Pain"},{"key":"530_CR73","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1042\/ETLS20200018","volume":"4","author":"DI Friedman","year":"2020","unstructured":"Friedman DI, Cohen JM. Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine. Emerg Top Life Sci. 2020;4:179\u201390. https:\/\/doi.org\/10.1042\/ETLS20200018.","journal-title":"Emerg Top Life Sci."},{"key":"530_CR74","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1212\/WNL.96.15_supplement.4171","volume":"96","author":"JM Cohen","year":"2021","unstructured":"Cohen JM, et al. Real-world reductions in migraine and headache days for patients with chronic and episodic migraine initiating Fremanezumab in the US (4171). Neurology. 2021;96:4171.","journal-title":"Neurology"},{"key":"530_CR75","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2217\/pmt-2021-0015","volume":"11","author":"M Ashina","year":"2021","unstructured":"Ashina M, et al. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine. Pain Manag. 2021;11:647\u201354. https:\/\/doi.org\/10.2217\/pmt-2021-0015.","journal-title":"Pain Manag"},{"issue":"Suppl 2","key":"530_CR76","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/head.13583","volume":"59","author":"H Yuan","year":"2019","unstructured":"Yuan H, Spare NM, Silberstein SD. Targeting CGRP for the prevention of migraine and cluster headache: a narrative review. Headache. 2019;59(Suppl 2):20\u201332. https:\/\/doi.org\/10.1111\/head.13583.","journal-title":"Headache"},{"key":"530_CR77","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-3-030-69032-8_8","volume-title":"Monoclonal antibodies in headache","author":"H Yuan","year":"2021","unstructured":"Yuan H, Silberstein SD. Eptinezumab. In: van den Brink AM, Martelletti P, editors. Monoclonal antibodies in headache. Cham: Springer; 2021. p. 109\u201319."},{"key":"530_CR78","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.567","volume":"8","author":"B Baker","year":"2020","unstructured":"Baker B, et al. Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine. Pharmacol Res Perspect. 2020;8: e00567. https:\/\/doi.org\/10.1002\/prp2.567.","journal-title":"Pharmacol Res Perspect"},{"key":"530_CR79","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1474-4422(14)70209-1","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13:1100\u20137. https:\/\/doi.org\/10.1016\/S1474-4422(14)70209-1.","journal-title":"Lancet Neurol"},{"key":"530_CR80","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1177\/0333102419858355","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, et al. Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia. 2019;39:1075\u201385. https:\/\/doi.org\/10.1177\/0333102419858355.","journal-title":"Cephalalgia"},{"key":"530_CR81","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40:241\u201354. https:\/\/doi.org\/10.1177\/0333102420905132.","journal-title":"Cephalalgia"},{"issue":"2254\u20132265","key":"530_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.11.007","volume":"42","author":"TR Smith","year":"2020","unstructured":"Smith TR, et al. Eptinezumab for the prevention of episodic migraine: sustained effect through 1 year of treatment in the PROMISE-1 study. Clin Ther. 2020;42(2254\u20132265): e3. https:\/\/doi.org\/10.1016\/j.clinthera.2020.11.007.","journal-title":"Clin Ther"},{"key":"530_CR83","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94:e1365\u201377. https:\/\/doi.org\/10.1212\/WNL.0000000000009169.","journal-title":"Neurology"},{"key":"530_CR84","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-020-01186-3","volume":"21","author":"S Silberstein","year":"2020","unstructured":"Silberstein S, et al. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. J Headache Pain. 2020;21:120. https:\/\/doi.org\/10.1186\/s10194-020-01186-3.","journal-title":"J Headache Pain"},{"key":"530_CR85","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1001\/jama.2021.7665","volume":"325","author":"PK Winner","year":"2021","unstructured":"Winner PK, et al. Effects of intravenous eptinezumab vs. placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. JAMA. 2021;325:2348\u201356. https:\/\/doi.org\/10.1001\/jama.2021.7665.","journal-title":"JAMA"},{"key":"530_CR86","doi-asserted-by":"crossref","unstructured":"Kudrow DLR, Silberstein S, Cady R, Schaeffler B, Biondi D, Smith J. Eptinezumab for prevention of chronic migraine: results of 2 infusions in the phase 3 PROMISE-2 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy\u20132) Trial. Neurology. 2019;92 (15 supplement)","DOI":"10.1212\/WNL.92.15_supplement.P2.10-006"},{"key":"530_CR87","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12883-021-02123-w","volume":"21","author":"D Kudrow","year":"2021","unstructured":"Kudrow D, et al. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol. 2021;21:126. https:\/\/doi.org\/10.1186\/s12883-021-02123-w.","journal-title":"BMC Neurol"},{"key":"530_CR88","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18032","volume":"13","author":"A Datta","year":"2021","unstructured":"Datta A, Maryala S, John R. A review of eptinezumab use in migraine. Cureus. 2021;13: e18032. https:\/\/doi.org\/10.7759\/cureus.18032.","journal-title":"Cureus."},{"key":"530_CR89","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-3-030-75239-2_5","volume-title":"Migraine","author":"H Yuan","year":"2021","unstructured":"Yuan H, Silberstein S. CGRP and immune modulation: evidence-based therapy. In: Shah S, editor. Migraine. Irvine: Springer; 2021. p. 75\u201394."},{"key":"530_CR90","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa030505","volume":"350","author":"J Olesen","year":"2004","unstructured":"Olesen J, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350:1104\u201310. https:\/\/doi.org\/10.1056\/NEJMoa030505.","journal-title":"N Engl J Med"},{"key":"530_CR91","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(08)61626-8","volume":"372","author":"TW Ho","year":"2008","unstructured":"Ho TW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372:2115\u201323. https:\/\/doi.org\/10.1016\/S0140-6736(08)61626-8.","journal-title":"Lancet"},{"key":"530_CR92","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1212\/01.WNL.0000286940.29755.61","volume":"70","author":"TW Ho","year":"2008","unstructured":"Ho TW, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70:1304\u201312. https:\/\/doi.org\/10.1212\/01.WNL.0000286940.29755.61.","journal-title":"Neurology"},{"key":"530_CR93","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1177\/0333102411398399","volume":"31","author":"DJ Hewitt","year":"2011","unstructured":"Hewitt DJ, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011;31:712\u201322. https:\/\/doi.org\/10.1177\/0333102411398399.","journal-title":"Cephalalgia"},{"key":"530_CR94","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","volume":"83","author":"TW Ho","year":"2014","unstructured":"Ho TW, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014;83:958\u201366. https:\/\/doi.org\/10.1212\/WNL.0000000000000771.","journal-title":"Neurology"},{"key":"530_CR95","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/head.13791","volume":"60","author":"D Tepper","year":"2020","unstructured":"Tepper D. Gepants. Headache. 2020;60:1037\u20139. https:\/\/doi.org\/10.1111\/head.13791.","journal-title":"Headache"},{"key":"530_CR96","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1468-2982.2004.00726.x","volume":"24","author":"M Iovino","year":"2004","unstructured":"Iovino M, et al. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia. 2004;24:645\u201356. https:\/\/doi.org\/10.1111\/j.1468-2982.2004.00726.x.","journal-title":"Cephalalgia"},{"key":"530_CR97","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.clpt.2004.10.001","volume":"77","author":"KA Petersen","year":"2005","unstructured":"Petersen KA, et al. BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther. 2005;77:202\u201313. https:\/\/doi.org\/10.1016\/j.clpt.2004.10.001.","journal-title":"Clin Pharmacol Ther"},{"key":"530_CR98","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1111\/head.12179","volume":"53","author":"ME Bigal","year":"2013","unstructured":"Bigal ME, Walter S, Rapoport AM. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache. 2013;53:1230\u201344. https:\/\/doi.org\/10.1111\/head.12179.","journal-title":"Headache"},{"key":"530_CR99","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1177\/0091270010361741","volume":"50","author":"TH Han","year":"2010","unstructured":"Han TH, et al. Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. J Clin Pharmacol. 2010;50:1367\u201376. https:\/\/doi.org\/10.1177\/0091270010361741.","journal-title":"J Clin Pharmacol"},{"key":"530_CR100","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1526-4610.2011.01860.x","volume":"51","author":"DJ Hewitt","year":"2011","unstructured":"Hewitt DJ, et al. Randomized controlled study of telcagepant plus ibuprofen or acetaminophen in migraine. Headache. 2011;51:533\u201343. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.01860.x.","journal-title":"Headache"},{"key":"530_CR101","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1212\/WNL.0b013e3181b87942","volume":"73","author":"KM Connor","year":"2009","unstructured":"Connor KM, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009;73:970\u20137. https:\/\/doi.org\/10.1212\/WNL.0b013e3181b87942.","journal-title":"Neurology"},{"key":"530_CR102","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2147\/JPR.S244249","volume":"14","author":"CC Chiang","year":"2021","unstructured":"Chiang CC, VanderPluym JH. Ubrogepant in the acute management of migraine: a narrative review. J Pain Res. 2021;14:1185\u201392. https:\/\/doi.org\/10.2147\/JPR.S244249.","journal-title":"J Pain Res"},{"key":"530_CR103","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0333102416653233","volume":"36","author":"T Voss","year":"2016","unstructured":"Voss T, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36:887\u201398. https:\/\/doi.org\/10.1177\/0333102416653233.","journal-title":"Cephalalgia"},{"key":"530_CR104","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381:2230\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1813049.","journal-title":"N Engl J Med"},{"key":"530_CR105","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, et al. Effect of ubrogepant vs. placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322:1887\u201398. https:\/\/doi.org\/10.1001\/jama.2019.16711.","journal-title":"JAMA"},{"key":"530_CR106","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40120-021-00234-7","volume":"10","author":"S Hutchinson","year":"2021","unstructured":"Hutchinson S, et al. Ubrogepant for the acute treatment of migraine: pooled efficacy, safety, and tolerability from the ACHIEVE I and ACHIEVE II phase 3 randomized trials. Neurol Ther. 2021;10:235\u201349. https:\/\/doi.org\/10.1007\/s40120-021-00234-7.","journal-title":"Neurol Ther."},{"key":"530_CR107","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/head.13766","volume":"60","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, et al. Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, ACHIEVE I and II. Headache. 2020;60:686\u2013700. https:\/\/doi.org\/10.1111\/head.13766.","journal-title":"Headache"},{"key":"530_CR108","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1212\/WNL.94.15_supplement.2145","volume":"94","author":"C Conway","year":"2020","unstructured":"Conway C, et al. Phase 1 and 2 safety, tolerability and pharmacokinetics of single and multiple dose rimegepant as compared to the predicted clinically efficacious dose range (2145). Neurology. 2020;94:2145.","journal-title":"Neurology"},{"key":"530_CR109","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0333102413500727","volume":"34","author":"R Marcus","year":"2014","unstructured":"Marcus R, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34:114\u201325. https:\/\/doi.org\/10.1177\/0333102413500727.","journal-title":"Cephalalgia"},{"key":"530_CR110","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381:142\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1811090.","journal-title":"N Engl J Med"},{"key":"530_CR111","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394:737\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(19)31606-X.","journal-title":"Lancet"},{"key":"530_CR112","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3389\/fphar.2019.01577","volume":"10","author":"B Gao","year":"2019","unstructured":"Gao B, et al. Efficacy and safety of rimegepant for the acute treatment of migraine: evidence from randomized controlled trials. Front Pharmacol. 2019;10:1577. https:\/\/doi.org\/10.3389\/fphar.2019.01577.","journal-title":"Front Pharmacol"},{"key":"530_CR113","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, et al. Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:51\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)32544-7.","journal-title":"Lancet"},{"key":"530_CR114","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/cpdd.916","volume":"10","author":"R Boinpally","year":"2021","unstructured":"Boinpally R, et al. Single-dose pharmacokinetics and safety of atogepant in adults with hepatic impairment: results from an open-label, phase 1 trial. Clin Pharmacol Drug Dev. 2021;10:726\u201333. https:\/\/doi.org\/10.1002\/cpdd.916.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"530_CR115","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/cpdd.940","volume":"10","author":"R Boinpally","year":"2021","unstructured":"Boinpally R, et al. A single supratherapeutic dose of atogepant does not affect cardiac repolarization in healthy adults: results from a randomized, single-dose, phase 1 crossover trial. Clin Pharmacol Drug Dev. 2021;10:1099\u2013107. https:\/\/doi.org\/10.1002\/cpdd.940.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"530_CR116","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","volume":"19","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial. Lancet Neurol. 2020;19:727\u201337. https:\/\/doi.org\/10.1016\/S1474-4422(20)30234-9.","journal-title":"Lancet Neurol"},{"key":"530_CR117","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385:695\u2013706. https:\/\/doi.org\/10.1056\/NEJMoa2035908.","journal-title":"N Engl J Med"},{"key":"530_CR118","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/cts.12917","volume":"14","author":"KC Min","year":"2021","unstructured":"Min KC, et al. Atogepant is not associated with clinically meaningful alanine aminotransferase elevations in healthy adults. Clin Transl Sci. 2021;14:599\u2013605. https:\/\/doi.org\/10.1111\/cts.12917.","journal-title":"Clin Transl Sci"},{"key":"530_CR119","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1212\/WNL.96.15_supplement.1145","volume":"96","author":"A Jakate","year":"2021","unstructured":"Jakate A, et al. Single therapeutic doses of atogepant are not associated with a clinically relevant drug-drug interaction when coadministered with acetaminophen or naproxen (1145). Neurology. 2021;96:1145.","journal-title":"Neurology"},{"key":"530_CR120","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1212\/WNL.96.15_supplement.1140","volume":"96","author":"M Butler","year":"2021","unstructured":"Butler M, et al. Coadministration of single therapeutic oral doses of atogepant and sumatriptan produces no clinically relevant drug\u2013drug interactions (1140). Neurology. 2021;96:1140.","journal-title":"Neurology"},{"key":"530_CR121","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcph.1610","volume":"60","author":"W Ankrom","year":"2020","unstructured":"Ankrom W, et al. Atogepant has no clinically relevant effects on the pharmacokinetics of an ethinyl estradiol\/levonorgestrel oral contraceptive in healthy female participants. J Clin Pharmacol. 2020;60:1157\u201365. https:\/\/doi.org\/10.1002\/jcph.1610.","journal-title":"J Clin Pharmacol"},{"key":"530_CR122","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/WCO.0000000000000806","volume":"33","author":"D Moreno-Ajona","year":"2020","unstructured":"Moreno-Ajona D, Perez-Rodriguez A, Goadsby PJ. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? Curr Opin Neurol. 2020;33:309\u201315. https:\/\/doi.org\/10.1097\/WCO.0000000000000806.","journal-title":"Curr Opin Neurol"},{"key":"530_CR123","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3390\/jcm10071429","volume":"10","author":"M Capi","year":"2021","unstructured":"Capi M, et al. CGRP receptor antagonists and 5-HT1F receptor agonist in the treatment of migraine. J Clin Med. 2021;10:1429. https:\/\/doi.org\/10.3390\/jcm10071429.","journal-title":"J Clin Med"},{"key":"530_CR124","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1212\/WNL.96.15_supplement.4976","volume":"96","author":"R Croop","year":"2021","unstructured":"Croop R, et al. Intranasal zavegepant is effective and well tolerated for the acute treatment of migraine: a phase 2\/3 dose-ranging clinical trial (4976). Neurology. 2021;96:4976.","journal-title":"Neurology"},{"key":"530_CR125","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.amjms.2021.02.019","volume":"361","author":"PP Mehta","year":"2021","unstructured":"Mehta PP, Dhapte-Pawar VS. Novel and evolving therapies for COVID-19 related pulmonary complications(). Am J Med Sci. 2021;361:557\u201366. https:\/\/doi.org\/10.1016\/j.amjms.2021.02.019.","journal-title":"Am J Med Sci"},{"key":"530_CR126","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.coph.2004.01.006","volume":"4","author":"A Dakhama","year":"2004","unstructured":"Dakhama A, Larsen GL, Gelfand EW. Calcitonin gene-related peptide: role in airway homeostasis. Curr Opin Pharmacol. 2004;4:215\u201320. https:\/\/doi.org\/10.1016\/j.coph.2004.01.006.","journal-title":"Curr Opin Pharmacol"},{"key":"530_CR127","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, et al. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021\u201339. https:\/\/doi.org\/10.1111\/head.14153.","journal-title":"Headache"},{"key":"530_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"American Headache Society","year":"2019","unstructured":"American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1\u201318. https:\/\/doi.org\/10.1111\/head.13456.","journal-title":"Headache"},{"key":"530_CR129","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20:6. https:\/\/doi.org\/10.1186\/s10194-018-0955-y.","journal-title":"J Headache Pain"},{"key":"530_CR130","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.4103\/0028-3886.315991","volume":"69","author":"A Singh","year":"2021","unstructured":"Singh A, Gupta D, Singh A. Ditans vs. gepants: a systematic review and indirect network meta-analysis for comparative analysis of efficacy and safety. Neurol India. 2021;69:S43\u201350. https:\/\/doi.org\/10.4103\/0028-3886.315991.","journal-title":"Neurol India."},{"key":"530_CR131","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28544","volume":"4","author":"CP Yang","year":"2021","unstructured":"Yang CP, et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open. 2021;4: e2128544. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.28544.","journal-title":"JAMA Netw Open"},{"key":"530_CR132","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/14656566.2020.1862793","volume":"22","author":"A Negro","year":"2021","unstructured":"Negro A, Martelletti P. Novel synthetic treatment options for migraine. Expert Opin Pharmacother. 2021;22:907\u201322. https:\/\/doi.org\/10.1080\/14656566.2020.1862793.","journal-title":"Expert Opin Pharmacother"},{"key":"530_CR133","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0333102419884943","volume":"40","author":"E Rubio-Beltran","year":"2020","unstructured":"Rubio-Beltran E, et al. Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries. Cephalalgia. 2020;40:357\u201366. https:\/\/doi.org\/10.1177\/0333102419884943.","journal-title":"Cephalalgia"},{"issue":"Suppl 1","key":"530_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.14130","volume":"61","author":"FG Freitag","year":"2021","unstructured":"Freitag FG, Tolebeyan A, Sivakumar D. CGRP monoclonal antibodies along with CGRP receptor antagonists are safe and effective together and compared to standard of care. Headache. 2021;61(Suppl 1):1\u2013178. https:\/\/doi.org\/10.1111\/head.14130.","journal-title":"Headache"},{"key":"530_CR135","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/head.13930","volume":"60","author":"G Berman","year":"2020","unstructured":"Berman G, et al. Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine. Headache. 2020;60:1734\u201342. https:\/\/doi.org\/10.1111\/head.13930.","journal-title":"Headache"},{"issue":"Suppl 1","key":"530_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.14130","volume":"61","author":"L Mueller","year":"2021","unstructured":"Mueller L. Gepant efficacy when combined with a CGRP monoclonal antibody: a retrospective chart review. Headache. 2021;61(Suppl 1):1\u2013178. https:\/\/doi.org\/10.1111\/head.14130.","journal-title":"Headache"},{"key":"530_CR137","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/head.13843","volume":"60","author":"L Pellesi","year":"2020","unstructured":"Pellesi L, et al. Dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: is there a rationale? Headache. 2020;60:1056\u201365. https:\/\/doi.org\/10.1111\/head.13843.","journal-title":"Headache"},{"key":"530_CR138","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1093\/pm\/pnab093","volume":"22","author":"F Cohen","year":"2021","unstructured":"Cohen F, et al. Efficacy and tolerability of calcitonin gene-related peptide-targeted monoclonal antibody medications as add-on therapy to onabotulinumtoxina in patients with chronic migraine. Pain Med. 2021;22:1857\u201363. https:\/\/doi.org\/10.1093\/pm\/pnab093.","journal-title":"Pain Med"},{"key":"530_CR139","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-021-00264-x","author":"AM Blumenfeld","year":"2021","unstructured":"Blumenfeld AM, et al. Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxina: a retrospective chart review. Pain Ther. 2021. https:\/\/doi.org\/10.1007\/s40122-021-00264-x.","journal-title":"Pain Ther"},{"key":"530_CR140","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3390\/pharmaceutics12121180","volume":"12","author":"D Szkutnik-Fiedler","year":"2020","unstructured":"Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug\u2013drug interactions of new anti-migraine drugs-lasmiditan, gepants, and Calcitonin-Gene-Related Peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020;12:1180. https:\/\/doi.org\/10.3390\/pharmaceutics12121180.","journal-title":"Pharmaceutics"},{"key":"530_CR141","doi-asserted-by":"publisher","DOI":"10.1111\/head.14244","author":"J Ailani","year":"2021","unstructured":"Ailani J, Blumenfeld AM. Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine. Headache. 2021. https:\/\/doi.org\/10.1111\/head.14244.","journal-title":"Headache"},{"key":"530_CR142","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211048765","author":"LH Overeem","year":"2021","unstructured":"Overeem LH, et al. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia. 2021. https:\/\/doi.org\/10.1177\/03331024211048765.","journal-title":"Cephalalgia"},{"key":"530_CR143","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/head.14259","volume":"62","author":"RB Lipton","year":"2022","unstructured":"Lipton RB, et al. Diagnosis, consultation, treatment, and impact of migraine in the US: results of the OVERCOME (US) study. Headache. 2022;62:122\u201340. https:\/\/doi.org\/10.1111\/head.14259.","journal-title":"Headache"},{"key":"530_CR144","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-021-01378-5","volume":"23","author":"K Johnston","year":"2022","unstructured":"Johnston K, et al. Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant\u2014post hoc results from an open label safety study (BHV3000-201). J Headache Pain. 2022;23:10. https:\/\/doi.org\/10.1186\/s10194-021-01378-5.","journal-title":"J Headache Pain"},{"key":"530_CR145","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/head.14258","volume":"62","author":"AK Kawata","year":"2022","unstructured":"Kawata AK, et al. Reducing the physical, social, and emotional impact of episodic migraine: results from erenumab STRIVE and ARISE phase III randomized trials. Headache. 2022;62:159\u201368. https:\/\/doi.org\/10.1111\/head.14258.","journal-title":"Headache"},{"key":"530_CR146","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01115-5","author":"SJ Tepper","year":"2022","unstructured":"Tepper SJ, et al. Effects of galcanezumab on health-related quality of life and disability in patients with previous failure of 2\u20134 migraine preventive medication categories: results from a phase IIIb randomized, placebo-controlled, multicenter clinical trial (CONQUER). Clin Drug Investig. 2022. https:\/\/doi.org\/10.1007\/s40261-021-01115-5.","journal-title":"Clin Drug Investig"},{"key":"530_CR147","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1111\/head.14196","volume":"61","author":"ELH Spierings","year":"2021","unstructured":"Spierings ELH, et al. Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study. Headache. 2021;61:1376\u201386. https:\/\/doi.org\/10.1111\/head.14196.","journal-title":"Headache"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00530-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-022-00530-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00530-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T07:13:37Z","timestamp":1744701217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-022-00530-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":147,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["530"],"URL":"https:\/\/doi.org\/10.1007\/s40259-022-00530-0","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]},"assertion":[{"value":"21 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This paper received no funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"F.C. has no conflicts of interest or financial disclosures. H.Y. has previously served as a consultant for Supernus Pharmaceuticals, Inc. and Trillen Medical Inc, and currently receives research grants from NIH (R44NS115460). S.S. receives honoraria from Alder Biopharmaceuticals; Allergan, Inc.; Amgen; Avanir Pharmaceuticals, Inc.; Depomed; Dr. Reddy\u2019s Laboratories; eNeura Inc.; electroCore Medical, LLC; Ipsen Biopharmaceuticals; Medscape, LLC; Medtronic, Inc.; Mitsubishi Tanabe Pharma America, Inc.; NINDS; St. Jude Medical; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals and Trigemina, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"F.C. H.Y., and S.S. were involved in the design, writing, and revision of this article.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}